Source: Annual Congress 2001 - New developments in inhaler delivery systems
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. J. Langley, B. McDonnell, D. Allen, N. Wheeler, M. Briggs, A. A. Woodcock (Manchester, Uxbridge, United Kingdom). Effect of fine particle mass (FPM) on the bronchodilator and bronchoprotective properties of salmeterol. Eur Respir J 2001; 16: Suppl. 31, 715

Member's Comments

No comment yet.

Related content which might interest you: Inhaled long-acting β2-agonist: aerosol particle size and bronchodilator response Source: Eur Respir J 2005; 26: Suppl. 49, 126s Year: 2005 Fine particle mass of salbutamol: diskus and turbuhaler in vitro compared Source: Eur Respir J 2002; 20: Suppl. 38, 499s Year: 2002 Lung deposition and distribution of inhaled extra fine beclomethasone dipropionate / formoterol fumarate /glycopyrronium bromide (BDP/FF/GB) in subjects with and without airflow obstruction. Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Effects of extra fine formoterol or coarse particle salmeterol on impulse oscillometry (IOS) in corticosteroid treated persistent asthmatics Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Bronchodilator effect of formoterol delivered by two different dry powder inhalers (DPI) Source: Eur Respir J 2004; 24: Suppl. 48, 310s Year: 2004 Comparison of the anti-inflammatory effects of extra-fine HFA-beclomethasone (BDP) versus fluticasone (FP)-DPI on inflammatory markers in exhaled breath in childhood asthma Source: Annual Congress 2007 - Childhood asthma: treatment and follow-up Year: 2007 Bronchoprotective and anti-inflammatory effect of beclometasone dipropionate plus formoterol HFA fixed combination in asthmatic patients Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Reduction in air trapping and dyspnea with an extrafine combination of beclomethasone and formoterol in COPD Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Effect of montelukast or salmeterol added to inhaled fluticasone on response to albuterol in children with exercise-induced bronchoconstriction Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Duration of the effect of inhaled salmeterol on walking distance Source: Eur Respir J 2002; 20: Suppl. 38, 114s Year: 2002 Beclomethasone, formoterol and glycopyrronium: ceiling effect in small airways of COPD patients Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020 Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol Source: Eur Respir J 2001; 17: 368-373 Year: 2001 Protective effect of inhaled glucocorticosteroid and long-acting beta2-agonist combination on COPD model Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases Year: 2021 Protective effect of inhaled beclomethasone dipropionate (BDP) in asthmatic patients with exercise-induced bronchoconstriction (EIB) Source: Eur Respir J 2002; 20: Suppl. 38, 306s Year: 2002 The small airway inflammation of asthmatic patients who have used dry powder type inhaled steroid for moderate-long term evaluated by induced sputum and the efficacy of HFA-BDP (QVAR) inhalation Source: Eur Respir J 2005; 26: Suppl. 49, 503s Year: 2005 Comparison of the bronchoprotective effects of two salbutamol suplphate HFA pMDI using methacholine challenge testing Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 Effects of procaterol or salmeterol added to maintenance tiotropium therapy on small airway functions in COPD patients Source: Annual Congress 2010 - COPD: management Year: 2010 In vitro analysis of two formulations of fluticasone/ salmeterol pMDI for delivered dose uniformity and aerodynamic particle size distribution Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 The bronchodilatory effect of NVA237 inhaled once daily in patients with COPD Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD Source: Eur Respir J 2003; 21: 86-94 Year: 2003